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Edited by Jesus AvilaAbstract Type 2 diabetes mellitus (DM) and Alzheimers dis-
ease (AD) share epidemiological and biochemical features. Both
are characterized by insoluble protein aggregates with a ﬁbrillar
conformation – amylin in Type 2 DM pancreatic islets, and Ab
in AD brain. To determine whether amylin shares neurotoxic
properties with Ab, we incubated hippocampal and cortical neu-
rons with Ab42 and human amylin. Diﬀerent from non-amyloido-
genic rat amylin, both caused a dose-, time- and cell type-speciﬁc
neurotoxicity supporting the notion of a similar toxic mecha-
nism. Depending on the cell type, this ﬁnding is also supported
by co-incubation of human amylin and Ab.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Ab42 amyloid; Alzheimers disease; Amylin; Cell-
type speciﬁcity; Conformational disease; IAPP; Neurotoxicity;
Type 2 diabetes mellitus1. Introduction
Type 2 diabetes mellitus (DM) and Alzheimers disease (AD)
are chronic diseases and both are leading causes of morbidity
and mortality in the elderly. Type 2 DM accounts for 90% of
all cases of diabetes and is characterized by resistance of target
tissue to insulin and subsequently, elevated blood glucose lev-
els. Disease progression is associated with increased deposition
of amyloid-like amylin, also known as the islet amyloid poly-
peptide (IAPP), in insulin-producing pancreatic islet b-cells
[1]. Amylin is a member of structurally and functionally related
peptides which include calcitonin, adrenomedullin and calcito-
nin gene related peptide [2]. In humans, IAPP is synthesized as
a 67-residue propeptide and colocalized with insulin in b-cell
granules. The mature 37-amino acid peptide is produced by
proteolysis (Fig. 1). Both in vitro and in vivo studies revealed
that its formation is associated with b-cell death [1,3]. Type 2
DM can be deﬁned as a conformational disease because amylin
undergoes a change in tertiary structure followed by self-asso-
ciation and deposition [4]. Type 2 DM has been modelled by
injecting streptozotocin [5] and in the ob/ob (leptin knockout),
db/db (leptin receptor knockout), both of which are insulin
resistant, and in mice with transgenic over-expression of IAPP
in pancreatic islets [6–8]. Breeding the IAPP transgenic mice to
homozygosity causes islet amylin aggregation, b-cell death and*Corresponding author. Fax: +61 2 9351 0731.
E-mail address: jgoetz@med.usyd.edu.au (J. Go¨tz).
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doi:10.1016/j.febslet.2008.05.006DM [8]. In conclusion, Type 2 DM is an amyloidosis and cur-
rent evidence suggests a major, yet poorly understood, role of
amylin in disease.
AD, for comparison, is a progressive neurodegenerative dis-
ease aﬀecting more than 15 million people worldwide. It is
characterized by progressive loss of memory and other cogni-
tive functions, resulting in dementia. Like Type 2 DM, AD can
also be deﬁned as a conformational disease. In AD brain, the
Ab peptide and the protein tau undergo a change in tertiary
structure followed by self-association and deposition in brain
[9]. Ab is the major constituent of b-amyloid plaques derived
from the precursor protein APP, with Ab42 being more ﬁbrill-
ogenic than Ab40. Hyperphosphorylated forms of the protein
tau are major constituents of neuroﬁbrillary tangles (NFTs)
[10]. In familial cases of AD, mutations were identiﬁed in the
APP gene itself and in genes encoding APP proteases. In fron-
totemporal dementia (FTD), mutations were identiﬁed in tau
[11–13]. We, along with others, utilized this information to de-
velop transgenic animal models and achieved Ab plaque and
NFT formation [13,14]. Signiﬁcant neuronal cell loss was
found upon massive over-expression of FTD mutant tau
[15]. Protein aggregates (such as Ab and tau) characterize
AD and FTD, but how Ab and tau cause nerve cell dysfunc-
tion and degeneration is still poorly understood [16].
Ab and human amylin are similar in size. They share little
similarities in their primary sequence (Fig. 1), but interestingly,
they fold into similar secondary structures. There is multiple
evidence that they may exert toxicity by binding to the same
receptor as, for example, antagonists of the amylin receptor
such as AC187 block Ab toxicity in rat cholinergic basal fore-
brain neurons [17]. Furthermore, both Ab and human amylin
can cause increased levels of APP, a putative Ab receptor, in
primary neuronal and astrocyte cultures [18]. Finally, distinct
integrin signalling pathways mediate both Ab- and amylin-in-
duced neurotoxicity, and both can be inhibited with integrin-
speciﬁc antibodies and cytochalasin D [19]. In support of the
notion that it is the tertiary rather than the primary structure
that is causing toxicity, treatment of cells with peptides that
do not fold into secondary structures under normal physiolog-
ical conditions, but that were aberrantly folded into b-sheet
structures caused signiﬁcant toxicity [20].
Therefore, the aim of this study was to establish, given the
similarities between human amylin and Ab, whether human
amylin exerts similar neurotoxic eﬀects as shown by Ab. In
addition, cell type speciﬁcity of toxicity was also explored by
comparing cortical to hippocampal cultures. Aged peptide
preparations were compared to non-aged preparations toblished by Elsevier B.V. All rights reserved.
Fig. 1. Alignment of the sequences of human (hu) and rat amylin and comparison to Ab42. Alignment of rat amylin (RA), human amylin (HA) and
Ab42. Grey shading shows similarities in the rat and human amylin sequences while important similarities between HA and Ab42 are shown
underlined.
Y.-A. Lim et al. / FEBS Letters 582 (2008) 2188–2194 2189ascertain the role of higher order oligomers as toxic agents. Fi-
nally, co-incubations of human amylin and Ab42 were per-
formed to elucidate whether the toxic eﬀects are additive
(suggestive of diﬀerent mechanisms) or not (by using the same
pathway).2. Methods and materials
2.1. Primary cortical cultures
Primary cortical neuronal cultures were prepared from 16.5-day-old
(E16.5) mouse embryos [21]. In brief, embryonic cultures were ob-
tained by sacriﬁcing time-mated C57Bl/6 female mice by cervical dislo-
cation, dissecting the brains, and removing the meninges from the
cortices. Cortical tissue was chopped up with a sterile razor blade into
small pieces (<1 mm) and transferred to a tube containing 0.025% (w/
v) trypsin (Sigma) in Hank Banks Salt Solution (HBSS, Sigma). After
incubation for 15 minutes at 37 C, DNase (Sigma) was added at
0.0008% (w/v) and the preparation was gently shaken, followed by cen-
trifugation at 720·g for 3 m at room temperature (RT). The superna-
tant was aspirated and the cortical tissue triturated 30 times in plating
media consisting of 10% FBS in DMEM using a plugged 1 ml auto-
claved pipette tip which resulted in a single cell suspension. Cells were
centrifuged at 720·g for 3 min at RT, the supernatant was removed
and the cell pellet resuspended in plating media. Total cell numbers
were determined using a Neubauer haemocytometer (Marienfeld, Ger-
many).
Cortical neurons were plated at a density of 30000 cells per cover
slip on 12 mm glass cover-slips in plating medium, which were pre-
coated with poly-L-lysine (Sigma). The coverslips were washed once
with PBS before cells were plated. The cultures were placed in a 5%
CO2 incubator at 37 C for 2 h to allow the cortical neurons to adhere
to the coverslips. Then, the plating medium was aspirated and cultures
cultivated for 20 days in Neurobasal medium supplemented with 1%
(v/v) B27 supplements (Gibco), 0.01% (v/v) 200 mM L-glutamine (Gib-
co) to minimize growth of microglia and astrocytes. A 50% medium
change was performed once every week.
2.2. Primary hippocampal cultures
Isolation and preparation of hippocampal cells were done similar to
the cortical cell preparations described above, with a few modiﬁca-
tions. Hippocampal cell cultures were prepared from 16.5-day-old
embryonic (E16.5) mice. Whole brains were isolated and meninges re-
moved as described above. In addition, the opaque horse shoe shaped
hippocampal region in each cortex was dissected using ﬁne forceps and
single cell suspension was prepared and plated using the same protocol
as above. The cultures were placed in a 5% CO2 incubator at 37 C for
2 h to allow the hippocampal neurons to adhere to the coverslips.
Then, the plating medium was aspirated and cultures cultivated for
20 days in Neurobasal medium supplemented with 1% (v/v) B27 sup-
plements (Gibco), 0.25% (v/v) 200 mM L-glutamine (Gibco) to mini-
mize growth of microglia and astrocytes. A 50% medium change was
performed once every week.
2.3. Preparation of amyloid peptides
Ab42, rat and human amylin were purchased from Bachem (Ger-
many) (H-9475 and H-7905, respectively). All chemicals were pur-
chased from Sigma unless otherwise stated. Ab42 was dissolved in
sterile PBS to a ﬁnal concentration of 250 lM and stored at 80 C
until use [22]. Human amylin and rat amylin were dissolved in
0.01 M acetic acid according to the manufacturers recommendations
to ﬁnal concentrations of 512 lM and 510 lM, respectively, and storedat 80 C until use. For the mock treatment the same ﬁnal concentra-
tion of acetic acid was used as for the amylin treatments. Peptides used
straight from the freezer are non-aged preparations. Aged peptides
were prepared by shaking them at 1000 rpm for 24 h at 37 C to allow
the formation of ﬁbrils.
2.4. Immunocytochemistry
Hippocampal and cortical neurons were treated after 20 days
in vitro (DIV). Ab stocks were diluted in Neurobasal medium (Gibco)
supplemented with 1% (v/v) B27 supplements (Gibco), and 0.25% (v/v)
200 mM L-glutamine (Gibco), at ﬁnal concentrations of 5 lM and
0.5 lM. Incubations were done for 4 days and all experiments were
done in triplicates.
To count the neurons following the incubations, we washed the cells
once with pre-warmed PBS to remove excess peptides and ﬁxed them
with 4% paraformaldehyde for 10 min at RT [23]. MAP2a + 2b anti-
body (Sigma, 1:500) speciﬁc for MAP2 was used to identify neurons.
As a secondary antibody, Alexa-ﬂuor 555 was used (Invitrogen,
1:250). DAPI was used to identify nuclei. All MAP-2 positive cells
and DAPI-positive nuclei in random, non-overlapping visual ﬁelds
were counted. Then, the ratio was calculated. Finally, all ratios were
normalized to that of vehicle treatment and expressed as percentage.
MAP2-positive cells were counted blinded by two investigators. Data
are shown as means ± standard error of the mean (S.E.M). Statistical
comparisons between groups were performed using ANOVA and post
hoc tests where conducted using SPSS version 11.3. Results and discussion
3.1. Peptide preparation and neuronal cultures
To determine cell-type-speciﬁc toxicity of human and rat
amylin compared to human Ab42, we treated cortical and hip-
pocampal cultures with these peptides. Furthermore, we used
non-aged and aged peptide preparations as it is well estab-
lished that aging of amyloidogenic peptides for 24 h at 37 C
promotes aggregation which can contribute to toxicity. Peptide
preparations were analysed on a 4–16% gradient tricine gel.
Coomassie staining revealed that, diﬀerent from rat amylin,
both the Ab42 and human amylin preparations contained high
order aggregates which did not enter the stacking gel (data not
shown).
We prepared both cortical and hippocampal neuronal cul-
tures. After 20 days in culture (20 DIV), the cells were ﬁxed
and stained with drebrin to determine whether the cultures
were fully diﬀerentiated. Staining revealed the presence of den-
dritic spines in both types of cultures, an indication of terminal
neuronal diﬀerentiation and thus, the possibility of comparing
the two cultures with respect to amyloid toxicity (Fig. 2A).
Representative pictures of a healthy and a non-viable neuron
are shown (Fig. 2B).
3.2. Amyloid toxicity in hippocampal neurons
Toxicity of human amylin towards islet b-cells has been
shown to depend on the aggregation state of amylin [24]. Based
on the aggregation state of rat and human amylin as well as
human Ab42, we expected that human amylin and Ab42
Fig. 2. (A) Primary cortical (Cx) and hippocampal (Hc) neuronal cultures stained for drebrin after 20 DIV (days in vitro). The insets show the
dendritic spines of the terminally diﬀerentiated neurons at a higher magniﬁcation. (B) A healthy (top) and a non-viable (bottom) neuron stained for
MAP2. Scale bar: 30 lm (A), 50 lm (B).
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case when 20 DIV hippocampal cultures were treated with
0.5 lM and 5 lM preparations for 3, 24, and 96 h (Fig. 3).
At 96 h, non-aged Ab42 was able to elicit toxicity at 5 lM
and this eﬀect was enhanced by aging the peptide that exerted
toxicity already at 0.5 lM (Fig. 3A and B). A similar dose-
dependency was also observed for human amylin, which
showed an enhanced neurotoxicity when the peptide was aged
compared to the non-aged preparation (Fig. 3C and D). Acetic
acid, which was used as solvent for amylin, did not exert tox-
icity. Although human amylin was more toxic than Ab, we
found a similar time-dependency under our experimental con-
ditions.
In contrast to human amylin and Ab42, rat amylin showed
either no or very little toxicity to hippocampal neurons at
the concentrations and time points tested (Fig. 3E and F). This
is consistent with studies in HeLa and b-cell lines where hu-
man, but not mouse amylin (which is similar to rat amylin)
has been shown to induce aggregation state-dependent apopto-
sis [25].
Together, as aging of rat amylin did not render it neurotoxic,
this suggests that a speciﬁc receptor–peptide interaction may
be involved in neurotoxicity. Rat amylin (RA) has been shown
before to form random globulars, and if this random change in
conformation does not elicit toxicity, then toxicity has to be
elicited by a speciﬁc change in conformation. Furthermore,
aging of human amylin and Ab42, both of which are known
to form extended ﬁbrils, causes enhanced toxicity in hippocam-
pal neurons. This suggests that the toxic species under our
experimental conditions are probably higher order polymers,
rather than monomers.
3.3. Amyloid toxicity in cortical neurons
Selective vulnerability has been reported in AD [26]. Specif-
ically, hippocampal neurons are the ﬁrst to degenerate duringAD before other brain areas are aﬀected. To investigate
whether this is also reﬂected by our system, we compared amy-
loid toxicity between hippocampal and cortical cultures. We
found that, diﬀerent from hippocampal cultures, cortical neu-
rons were generally less susceptible to peptide-induced toxicity
(Fig. 4). Aging Ab42 caused an earlier onset of toxicity
(Fig. 4A and B), which was also observed in the hippocampal
cultures. (Fig. 3A and B).
Similar to Ab42, aging of human amylin also enhanced its
neurotoxic properties (Fig. 4C and D); similar to what was
found for hippocampal cultures.
The above ﬁndings reinforce the idea that b-sheet structures
are important in conferring toxicity to amyloid, and more
importantly, that AD and Type 2 DM are conformational dis-
eases. Toxicity may correlate with the propensity of the pep-
tide to aggregate because the percentage of surviving neurons
after treatment with human amylin (HA), which aggregates
much faster than Ab42, was uniformly lower across all treat-
ment groups (for both hippocampal and cortical neurons) than
after treatment with Ab42.
The surprising ﬁnding was that 0.5 lM of aged rat amylin
was toxic to cortical neurons as early as 24 h. Rat amylin is
known not to form ﬁbrils, and aging of this peptide will only
lead to random globular structures. Thus, toxicity may be
attributed to an unspeciﬁc interaction to a receptor found
selectively in the cortical neurons but this has to be further
investigated.
3.4. Combined amyloid toxicity in hippocampal and cortical
neuronal cultures
Hippocampal neurons are generally more sensitive to toxic
insults. This was also found upon incubation of hippocampal
and cortical neurons with staurosporine, a non-selective pro-
tein kinase inhibitor that exerts its toxicity, in parts, by inter-
fering with multiple signalling pathways. We found that
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Fig. 3. Treatment of 20 DIV hippocampal neurons with non-aged and aged peptides for 3, 24, and 96 h. (A) Ab42 exerts a dose-dependent toxicity
on neurons which is enhanced upon aging. (B) HA also exerts a dose-dependent toxicity on neurons, like Ab42, and is enhanced upon aging of HA.
(C) RA is virtually not toxic to hippocampal neurons. All values are normalized against their respective vehicles and error bars represent the S.E.M.
*P < 0.05, **P < 0.001.
Y.-A. Lim et al. / FEBS Letters 582 (2008) 2188–2194 2191toxicity was much more pronounced with staurosporine than
with either Ab or human amylin (with up to 72% cell death)
(data not shown). As expected, hippocampal neurons were
more sensitive than cortical neurons, possibly reﬂecting
the generally higher content of supportive glia in cortical
cultures.
Aspects of Ab toxicity can be blocked in rat forebrain pri-
mary cultures using human amylin antagonists [26]. It has also
been suggested that Ab42 and human amylin may act on thesame receptor [16]. To investigate this possibility in our system,
we incubated hippocampal and cortical cultures with either
non-aged or aged Ab, human amylin or a combination of both
peptides for 24 h. We found that co-incubation of hippocam-
pal cultures with 5 lM non-aged Ab42 and 5 lM non-aged hu-
man amylin did not enhance toxicity compared to single
treatments (Fig. 5A), suggesting that the two peptides may
possibly act on the same pathway. In contrast, cortical neurons
showed an enhanced toxicity upon co-incubation (Fig. 5A).
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Fig. 4. Treatment of 20 DIV cortical neurons with non-aged and aged peptides for 3, 24, and 96 h. (A) Ab42 exerts a dose-dependent toxicity on
neurons which is enhanced upon aging of Ab42, like in the hippocampal cultures. The survival rate of the cortical cultures are higher than
hippocampal cultures. (B) HA also exerts a dose-dependent toxicity on neurons, like Ab42, and this is enhanced upon aging of HA. (C) RA is toxic to
cortical neurons but the eﬀect was not enhanced upon aging of RA. All values are normalized against their respective vehicles and error bars
represent S.E.M. *P < 0.05, **P < 0.001.
2192 Y.-A. Lim et al. / FEBS Letters 582 (2008) 2188–2194This suggests the possibility of more than one pathway in these
neurons in mediating toxicity of Ab42 and human amylin.
When we treated either hippocampal or cortical neurons
with aged peptides, human amylin alone already exerted a very
pronounced toxicity that was not further increased by Ab, sug-
gesting that this highly toxic nature of human amylin masks
any toxicity eﬀects of Ab42 (Fig. 5B).
In conclusion, we found that aggregation of Ab42 and hu-
man amylin enhanced their toxicity eﬀects uniformly acrossboth hippocampal and cortical cultures. This eﬀect was not ob-
served in cultures treated with rat amylin. We observed that in
general, hippocampal neurons were more sensitive than corti-
cal neurons to toxicity exerted by either human amylin or
Ab42. We also found that rat amylin, which does not form ﬁ-
brils, is virtually not toxic to hippocampal neurons but surpris-
ingly, it exerted toxicity in cortical neurons in our system.
Furthermore, co-incubation of Ab42 and human amylin
suggests the possibility of a shared pathway in hippocampal
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Fig. 5. Combined amyloid toxicity in hippocampal and cortical
neuronal cultures treated for 24 h with 5 lM aged preparations of
peptides. (A) Treatment of hippocampal and cortical neurons with Ab
and HA, either alone or in combination. Treatment of hippocampal
neurons suggests that HA and Ab use the same receptor or pathway to
exert toxicity whereas in cortical neurons they may use diﬀerent
receptors and/or pathways. (B) When using aged preparations, the
pronounced toxicity of human amylin likely masks that of Ab
precluding a conclusion as to whether the eﬀects of the two peptides
are additive or not. All values are normalized against their respective
vehicles and error bars represent S.E.M. *P < 0.05, **P < 0.001.
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cortical neurons. In future studies, antagonists may be utilized
to discriminate these possibilities. Our results suggest that spe-
ciﬁc conformational changes in peptides are important deter-
minants of toxicity. This notion is supported by the ﬁnding
that conformational antibodies can be generated that recog-
nize a generic amyloid ﬁbril epitope that is found, among
others, on amyloid-like aggregates derived from proteins such
as transthyretin, amylin or b2-microglobulin [27]. Further
studies involving expression of human and rat amylin in vivo
could aid in elucidating these mechanisms and possible interac-
tions to inhibit misfolding of proteins in diseases such as AD
and DM [13,24].
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